Phentermine-topiramate: First combination drug for obesity

Obesity is spreading globally at an alarming speed. The management of obesity is multifaceted and includes lifestyle modifications as the cornerstone. Until only orlistat was approved for long term use in obesity. The US Food and Drug Administration granted approval to a fixed dose mid 2012 combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Jagjit, Kumar, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
New Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456896/
https://www.ncbi.nlm.nih.gov/pubmed/26097830
http://dx.doi.org/10.4103/2229-516X.157177
_version_ 1782374908869738496
author Singh, Jagjit
Kumar, Rajiv
author_facet Singh, Jagjit
Kumar, Rajiv
author_sort Singh, Jagjit
collection PubMed
description Obesity is spreading globally at an alarming speed. The management of obesity is multifaceted and includes lifestyle modifications as the cornerstone. Until only orlistat was approved for long term use in obesity. The US Food and Drug Administration granted approval to a fixed dose mid 2012 combination of phentermine immediate release and topiramate extended release in 2012 for treatment of obese patients or overweight patients with comorbid conditions. The new drug has shown significant weight loss compared with placebo for a period up to 2 years.
format Online
Article
Text
id pubmed-4456896
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-44568962015-06-19 Phentermine-topiramate: First combination drug for obesity Singh, Jagjit Kumar, Rajiv Int J Appl Basic Med Res New Perspective Obesity is spreading globally at an alarming speed. The management of obesity is multifaceted and includes lifestyle modifications as the cornerstone. Until only orlistat was approved for long term use in obesity. The US Food and Drug Administration granted approval to a fixed dose mid 2012 combination of phentermine immediate release and topiramate extended release in 2012 for treatment of obese patients or overweight patients with comorbid conditions. The new drug has shown significant weight loss compared with placebo for a period up to 2 years. Medknow Publications & Media Pvt Ltd 2015 /pmc/articles/PMC4456896/ /pubmed/26097830 http://dx.doi.org/10.4103/2229-516X.157177 Text en Copyright: © International Journal of Applied and Basic Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle New Perspective
Singh, Jagjit
Kumar, Rajiv
Phentermine-topiramate: First combination drug for obesity
title Phentermine-topiramate: First combination drug for obesity
title_full Phentermine-topiramate: First combination drug for obesity
title_fullStr Phentermine-topiramate: First combination drug for obesity
title_full_unstemmed Phentermine-topiramate: First combination drug for obesity
title_short Phentermine-topiramate: First combination drug for obesity
title_sort phentermine-topiramate: first combination drug for obesity
topic New Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456896/
https://www.ncbi.nlm.nih.gov/pubmed/26097830
http://dx.doi.org/10.4103/2229-516X.157177
work_keys_str_mv AT singhjagjit phenterminetopiramatefirstcombinationdrugforobesity
AT kumarrajiv phenterminetopiramatefirstcombinationdrugforobesity

Ejemplares similares